Home LiteratureArticle Details
PMID: 10933070 Published · ppublish English Journal Article Research Support, U.S. Gov't, Non-P.H.S. Research Support, U.S. Gov't, P.H.S. Review

Characterizing tumors using metabolic imaging: PET imaging of cellular proliferation and steroid receptors.

Neoplasia (New York, N.Y.) ·Vol. 2 ·No. 1-2 ·2000-00-00 ·Pages 71-88

Mankoff DA, Dehdashti F, Shields AF

Abstract

Treatment decisions in oncology are increasingly guided by information on the biologic characteristics of tumors. Currently, patient-specific information on tumor biology is obtained from the analysis of biopsy material. Positron emission tomography (PET) provides quantitative estimates of regional biochemistry and receptor status and can overcome the sampling error and difficulty in performing serial studies inherent with biopsy. Imaging using the glucose metabolism tracer, 2 -deoxy-2- fluoro-D-glucose (FDG), has demonstrated PET's ability to guide therapy in clinical oncology. In this review, we highlight PET approaches to imaging two other aspects of tumor biology: cellular proliferation and tumor steroid receptors. We review the biochemical and biologic processes underlying the imaging, positron-emitting radiopharmaceuticals that have been developed, quantitative image-analysis considerations, and clinical studies to date. This provides a basis for evaluating future developments in these promising applications of PET metabolic imaging.

MeSH Terms
Cell Division Fluorodeoxyglucose F18/pharmacology Humans Magnetic Resonance Imaging Models, Biological Neoplasms/diagnostic imaging,pathology Radiopharmaceuticals/pharmacology Receptors, Steroid/metabolism Thymidine/chemistry Tomography, Emission-Computed/instrumentation,methods
Chemicals
Radiopharmaceuticals Receptors, Steroid Fluorodeoxyglucose F18 Thymidine
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Mankoff D A
Department of Radiology, University of Washington, Seattle, USA.
Dehdashti F
Shields A F
References (134)
134 references, click to expand
  1. 16 alpha-[77Br]bromoestradiol: dosimetry and preliminary clinical studies.
    J Nucl Med. 1982 May;23(5):425-30 PMID: 7077397
  2. Fundamental considerations in the design of fluorine-18 labeled progestins and androgens as imaging agents for receptor-positive tumors of the breast and prostate.
    Int J Rad Appl Instrum B. 1988;15(1):53-67 PMID: 3280523
  3. The biology of hormone refractory prostate cancer. Why does it develop?
    Urol Clin North Am. 1999 May;26(2):263-73 PMID: 10361549
  4. Imaging radiotracer model parameters in PET: a mixture analysis approach.
    IEEE Trans Med Imaging. 1993;12(3):399-412 PMID: 18218432
  5. In vitro assessment of 2-fluoro-2-deoxy-D-glucose, L-methionine and thymidine as agents to monitor the early response of a human adenocarcinoma cell line to radiotherapy.
    J Nucl Med. 1993 May;34(5):773-9 PMID: 8478710
  6. PET imaging of breast cancer with fluorine-18 radiolabeled estrogens and progestins.
    Q J Nucl Med. 1998 Mar;42(1):8-17 PMID: 9646640
  7. Cellular sources of thymidine nucleotides: studies for PET.
    J Nucl Med. 1987 Sep;28(9):1435-40 PMID: 3498017
  8. c-erbB-2 expression and response to adjuvant therapy in women with node-positive early breast cancer.
    N Engl J Med. 1994 May 5;330(18):1260-6 PMID: 7908410
  9. Oestrogen receptor status of primary breast carcinomas and their metastases. Relation to pattern of spread and survival after recurrence.
    Br J Cancer. 1989 Aug;60(2):252-7 PMID: 2765376
  10. Positron tomographic assessment of estrogen receptors in breast cancer: comparison with FDG-PET and in vitro receptor assays.
    J Nucl Med. 1995 Oct;36(10):1766-74 PMID: 7562040
  11. The role of positron emission tomography within the spectrum of medical imaging.
    Eur J Nucl Med. 1996 Feb;23(2):207-11 PMID: 8925858
  12. Predicting response to endocrine therapy in human breast cancer: a hypothesis.
    Science. 1975 Aug 29;189(4204):726-7 PMID: 168640
  13. Brain tumor imaging with PET and 2-[carbon-11]thymidine.
    J Nucl Med. 1994 Jun;35(6):974-82 PMID: 8195884
  14. Variation in receptor status between primary and metastatic breast cancer.
    Cancer. 1983 Aug 1;52(3):479-85 PMID: 6861087
  15. (2R*, 3S*)-1-[18F]fluoro-2,3-bis(4-hydroxyphenyl)pentane [( 18F]fluoronor-hexestrol), a positron-emitting estrogen that shows highly-selective, receptor-mediated uptake by target tissues in vivo.
    Life Sci. 1983 Nov 7;33(19):1933-8 PMID: 6316052
  16. Steroid hormone receptors in human breast cancer.
    Adv Cancer Res. 1983;38:61-75 PMID: 6349291
  17. Development of labeled thymidine analogs for imaging tumor proliferation.
    Nucl Med Biol. 1996 Jan;23(1):17-22 PMID: 9004909
  18. Carbon-11-thymidine and FDG to measure therapy response.
    J Nucl Med. 1998 Oct;39(10):1757-62 PMID: 9776283
  19. Endocrine treatment of breast cancer in women.
    Endocr Rev. 1990 May;11(2):221-65 PMID: 2194783
  20. Tracer feasibility for monitoring tumor radiotherapy: a quadruple tracer study with fluorine-18-fluorodeoxyglucose or fluorine-18-fluorodeoxyuridine, L-[methyl-14C]methionine, [6-3H]thymidine, and gallium-67.
    J Nucl Med. 1991 Nov;32(11):2118-23 PMID: 1834814
  21. Studies on 18F-labeled pyrimidines. Tumor uptakes of 18F-5-fluorouracil, 18F-5-fluorouridine, and 18F-5-fluorodeoxyuridine in animals.
    Eur J Nucl Med. 1983;8(6):258-61 PMID: 6223818
  22. The plasma sex steroid binding protein (SBP or SHBG). A critical review of recent developments on the structure, molecular biology and function.
    J Steroid Biochem Mol Biol. 1991;40(4-6):735-53 PMID: 1958572
  23. Hormone receptors in human prostate cancer.
    Scand J Urol Nephrol Suppl. 1988;107:39-45 PMID: 3287596
  24. Estrogen receptor analyses. Correlation of biochemical and immunohistochemical methods using monoclonal antireceptor antibodies.
    Arch Pathol Lab Med. 1985 Aug;109(8):716-21 PMID: 3893381
  25. The variability of estrogen receptors in metastatic breast cancer.
    Am J Surg. 1979 Feb;137(2):260-2 PMID: 426187
  26. Tamoxifen in the treatment of breast cancer.
    Ann Intern Med. 1988 Aug 1;109(3):219-28 PMID: 3291659
  27. Analysis of 2-carbon-11-thymidine blood metabolites in PET imaging.
    J Nucl Med. 1996 Feb;37(2):290-6 PMID: 8667064
  28. Relationship between plasma concentrations of 3'-deoxy-3'-fluorothymidine (alovudine) and antiretroviral activity in two concentration-controlled trials.
    J Infect Dis. 1994 Dec;170(6):1394-403 PMID: 7995977
  29. 16 beta-[18F]fluoromoxestrol: a potent, metabolically stable positron emission tomography imaging agent for estrogen receptor positive human breast tumors.
    Life Sci. 1993;53(10):811-9 PMID: 8355567
  30. Kinetics of [methyl-11C]thymidine in patients with squamous cell carcinoma of the head and neck.
    Acta Oncol. 1996;35(6):737-41 PMID: 8938223
  31. Spectral analysis of dynamic PET studies.
    J Cereb Blood Flow Metab. 1993 Jan;13(1):15-23 PMID: 8417003
  32. Selective alkylation of pyrimidyldianions: synthesis and purification of 11C labeled thymidine for tumor visualization using positron emission tomography.
    Int J Appl Radiat Isot. 1984 Aug;35(8):705-8 PMID: 6332784
  33. Chemotherapy for hormone refractory prostate cancer.
    Urol Clin North Am. 1999 May;26(2):323-31 PMID: 10361555
  34. Iododeoxyuridine uptake and retention as a measure of tumor growth.
    J Nucl Med. 1993 Jul;34(7):1152-62 PMID: 8315494
  35. The effect of plasma protein binding on the metabolism of steroid hormones.
    J Endocrinol. 1991 Dec;131(3):339-57 PMID: 1783881
  36. A graphical analysis method to estimate blood-to-tissue transfer constants for tracers with labeled metabolites.
    J Nucl Med. 1996 Dec;37(12):2049-57 PMID: 8970533
  37. The development of estrogen and progestin radiopharmaceuticals for imaging breast cancer.
    Anticancer Res. 1997 May-Jun;17(3B):1573-6 PMID: 9179196
  38. In vivo measurement of carbon-11 thymidine uptake in non-Hodgkin's lymphoma using positron emission tomography.
    J Nucl Med. 1988 Oct;29(10):1633-7 PMID: 3262725
  39. FDG uptake, tumour characteristics and response to therapy: a review.
    Nucl Med Commun. 1998 Feb;19(2):97-105 PMID: 9548192
  40. A fluorine-18 labeled progestin as an imaging agent for progestin receptor positive tumors with positron emission tomography.
    Cancer Res. 1991 Apr 1;51(7):1930-3 PMID: 2004378
  41. Oncological applications of positron emission tomography with fluorine-18 fluorodeoxyglucose.
    Eur J Nucl Med. 1996 Dec;23(12):1641-74 PMID: 8929320
  42. Radiolabeled nucleoside analogs in cancer diagnosis and therapy.
    Q J Nucl Med. 1996 Sep;40(3):301-19 PMID: 8961807
  43. Radiosyntheses of labeled beta-pseudothymidine ([C-11]- and [H-3]methyl) and its biodistribution and metabolism in normal and tumored mice.
    Nucl Med Biol. 1995 Jul;22(5):671-8 PMID: 7581179
  44. Assay of intracellular free and macromolecular-bound metabolites of 5-fluorodeoxyuridine and 5-fluorouracil.
    Cancer Res. 1979 Sep;39(9):3397-404 PMID: 157805
  45. Preclinical evaluation of fluorine-18-labeled androgen receptor ligands in baboons.
    J Nucl Med. 1996 Jun;37(6):1009-15 PMID: 8683293
  46. In vivo uptake of 131I-5-iodo-2-deoxyuridine by malignant tumours in man.
    Br J Cancer. 1991 Jan;63(1):134-5 PMID: 1989652
  47. Fluorine-18 deoxyglucose and false-positive results: a major problem in the diagnostics of oncological patients.
    Eur J Nucl Med. 1996 Oct;23(10):1409-15 PMID: 8781149
  48. The [14C]deoxyglucose method for the measurement of local cerebral glucose utilization: theory, procedure, and normal values in the conscious and anesthetized albino rat.
    J Neurochem. 1977 May;28(5):897-916 PMID: 864466
  49. In vitro and animal validation of bromine-76-bromodeoxyuridine as a proliferation marker.
    J Nucl Med. 1998 Jul;39(7):1273-9 PMID: 9669410
  50. PET imaging of brain tumor with [methyl-11C]choline.
    J Nucl Med. 1997 Jun;38(6):842-7 PMID: 9189127
  51. Detection of DNA synthesis in intact organisms with positron-emitting (methyl- 11 C)thymidine.
    Proc Natl Acad Sci U S A. 1972 Apr;69(4):988-92 PMID: 4554538
  52. The relationship of thymidine metabolism to the use of fractional incorporation as a measure of DNA synthesis and tissue proliferation.
    Eur J Cancer. 1978 Feb;14(2):153-68 PMID: 624312
  53. Tumor and organ biochemical profiles determined in vivo following uptake of a combination of radiolabeled substrates: potential applications for PET.
    Am J Physiol Imaging. 1992 Jan-Mar;7(1):2-11 PMID: 1520503
  54. Positron emission tomographic assessment of "metabolic flare" to predict response of metastatic breast cancer to antiestrogen therapy.
    Eur J Nucl Med. 1999 Jan;26(1):51-6 PMID: 9933662
  55. The synthesis of 18 F-5-fluorouracil. VII.
    J Nucl Med. 1973 Jan;14(1):63-4 PMID: 4682157
  56. Kinetic analysis of 2-[carbon-11]thymidine PET imaging studies: compartmental model and mathematical analysis.
    J Nucl Med. 1998 Jun;39(6):1043-55 PMID: 9627342
  57. Positron imaging feasibility studies. I: Characteristics of [3H]thymidine uptake in rodent and canine neoplasms: concise communication.
    J Nucl Med. 1981 Oct;22(10):869-74 PMID: 6974767
  58. Contribution of labeled carbon dioxide to PET imaging of carbon-11-labeled compounds.
    J Nucl Med. 1992 Apr;33(4):581-4 PMID: 1552344
  59. High performance liquid chromatography of carbon-11 labeled thymidine and its major catabolites for clinical PET studies.
    Nucl Med Biol. 1994 Nov;21(8):1045-51 PMID: 9234362
  60. The control of the interaction of sex hormone-binding globulin with its receptor by steroid hormones.
    J Biol Chem. 1990 Apr 15;265(11):6048-54 PMID: 2156840
  61. Distribution, metabolism, and excretion of 1-(2-fluoro-2-deoxy-beta-D- arabinofuranosyl)thymine and 1-(2-fluoro-2-deoxy-beta-D-arabinofuranosyl)-5- iodocytosine.
    Cancer Res. 1983 Aug;43(8):3619-27 PMID: 6305489
  62. The predictive value of estrogen and progesterone receptors' concentrations on the clinical behavior of breast cancer in women. Clinical correlation on 547 patients.
    Cancer. 1986 Mar 15;57(6):1171-80 PMID: 3943040
  63. Radiosynthesis and quality assurance of 5-[124I]Iodo-2'-deoxyuridine for functional PET imaging of cell proliferation.
    Nucl Med Biol. 1998 May;25(4):359-65 PMID: 9639297
  64. [Methyl-carbon-11] thymidine for in vivo measurement of cell proliferation.
    J Nucl Med. 1996 Jun;37(6):1048-52 PMID: 8683299
  65. THE UPTAKE OF INSPIRED 14CO2 INTO THE ACID-LABILE, THE ACID-SOLUBLE, THE LIPID, THE PROTEIN AND THE NUCLEIC ACID FRACTIONS OF RAT BRAIN TISSUE.
    Acta Physiol Scand. 1965 May-Jun;64:182-92 PMID: 14347277
  66. Preparation and evaluation of 17-ethynyl-substituted 16 alpha-[18F]fluoroestradiols: selective receptor-based PET imaging agents.
    Int J Rad Appl Instrum B. 1992 Apr;19(3):363-74 PMID: 1629026
  67. Diverging substrate specificity of pure human thymidine kinases 1 and 2 against antiviral dideoxynucleosides.
    J Biol Chem. 1991 May 15;266(14):9032-8 PMID: 2026611
  68. Synthesis of 2'-fluoro-5-[11C]-methyl-1-beta-D-arabinofuranosyluracil ([11C]-FMAU): a potential nucleoside analog for in vivo study of cellular proliferation with PET.
    Nucl Med Biol. 1995 Aug;22(6):783-9 PMID: 8535339
  69. The role of imaging in the development of oncologic agents.
    J Clin Pharmacol. 1999 Aug;Suppl:40S-44S PMID: 10434247
  70. Tamoxifen flare in advanced breast cancer.
    JAMA. 1978 Dec 8;240(24):2644-6 PMID: 712982
  71. The fate of 5-bromodeoxyuridine, 5-bromodeoxycytidine, and 5-iododeoxycytidine in man.
    Cancer Res. 1963 Feb;23:260-8 PMID: 14035826
  72. Application of robotics to radiopharmaceutical preparation: controlled synthesis of fluorine-18 16 alpha-fluoroestradiol-17 beta.
    J Nucl Med. 1986 May;27(5):714-21 PMID: 3486960
  73. The applications of PET in clinical oncology.
    J Nucl Med. 1991 Apr;32(4):623-48; discussion 649-50 PMID: 2013803
  74. Positron emission tomography with 2-[18F]Fluoro-2-deoxy-D-glucose and 16alpha-[18F]fluoro-17beta-estradiol in breast cancer: correlation with estrogen receptor status and response to systemic therapy.
    Clin Cancer Res. 1996 Jun;2(6):933-9 PMID: 9816253
  75. Analysis of blood clearance and labeled metabolites for the estrogen receptor tracer [F-18]-16 alpha-fluoroestradiol (FES).
    Nucl Med Biol. 1997 May;24(4):341-8 PMID: 9257333
  76. Kinetic analysis of 2-[11C]thymidine PET imaging studies: validation studies.
    J Nucl Med. 1999 Apr;40(4):614-24 PMID: 10210220
  77. 18F-5-Fluorouridine, a new probe for measuring the proliferation of tissue in vivo.
    Adv Enzyme Regul. 1982;20:3-22 PMID: 6180608
  78. 2-[C-11]thymidine imaging of malignant brain tumors.
    Cancer Res. 1999 Feb 1;59(3):615-21 PMID: 9973209
  79. Comparison of estrogen receptor levels in primary and regional metastatic carcinoma of the breast.
    Ann Surg. 1979 Jul;190(1):69-71 PMID: 464682
  80. Imaging of brain tumor proliferative activity with iodine-131-iododeoxyuridine.
    J Nucl Med. 1994 Sep;35(9):1407-17 PMID: 8071684
  81. 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone: synthesis and target tissue selective uptake of a progestin receptor based radiotracer for positron emission tomography.
    J Med Chem. 1988 Jul;31(7):1360-3 PMID: 3260285
  82. Can positron emission tomography (PET) be used to detect subclinical response to cancer therapy? The EC PET Oncology Concerted Action and the EORTC PET Study Group.
    Eur J Cancer. 1995 Nov;31A(12):1924-7 PMID: 8562143
  83. Production of [2-11C]thymidine for quantification of cellular proliferation with PET.
    Int J Rad Appl Instrum A. 1991;42(1):103-4 PMID: 1850393
  84. Target tissue uptake selectivity of three fluorine-substituted progestins: potential imaging agents for receptor-positive breast tumors.
    Int J Rad Appl Instrum B. 1990;17(3):309-19 PMID: 2341287
  85. Radiolabeled steroidal estrogens in cancer research.
    Steroids. 1993 Jun;58(6):245-59 PMID: 8212070
  86. Glucose metabolic rate kinetic model parameter determination in humans: the lumped constants and rate constants for [18F]fluorodeoxyglucose and [11C]deoxyglucose.
    J Cereb Blood Flow Metab. 1985 Jun;5(2):179-92 PMID: 3988820
  87. Automated production of 16alpha-[18F]fluoroestradiol for breast cancer imaging.
    Nucl Med Biol. 1999 May;26(4):473-9 PMID: 10382853
  88. The significance of residual mediastinal abnormality on the chest radiograph following treatment for Hodgkin's disease.
    J Clin Oncol. 1988 Jun;6(6):940-6 PMID: 3373265
  89. Metabolism of a [18F]fluorine labeled progestin (21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone) in humans: a clue for future investigations.
    Nucl Med Biol. 1994 Oct;21(7):941-52 PMID: 9234348
  90. Comparative breast tumor imaging and comparative in vitro metabolism of 16alpha-[18F]fluoroestradiol-17beta and 16beta-[18F]fluoromoxestrol in isolated hepatocytes.
    Nucl Med Biol. 1999 Jan;26(1):123-30 PMID: 10096512
  91. Thymidine transport in cultured mammalian cells. Kinetic analysis, temperature dependence and specificity of the transport system.
    Biochim Biophys Acta. 1979 May 17;553(2):262-83 PMID: 444518
  92. Assessment of 21-[18F]fluoro-16 alpha-ethyl-19-norprogesterone as a positron-emitting radiopharmaceutical for the detection of progestin receptors in human breast carcinomas.
    J Nucl Med. 1991 Aug;32(8):1532-7 PMID: 1869974
  93. Short-term thymidine uptake in normal and neoplastic tissues: studies for PET.
    J Nucl Med. 1984 Jul;25(7):759-64 PMID: 6610731
  94. Biologic markers as predictors of clinical outcome from systemic therapy for primary operable breast cancer.
    J Clin Oncol. 1999 Oct;17(10):3058-63 PMID: 10506600
  95. Positron tomographic assessment of 16 alpha-[18F] fluoro-17 beta-estradiol uptake in metastatic breast carcinoma.
    J Nucl Med. 1991 Aug;32(8):1526-31 PMID: 1869973
  96. Worsening bone scan in the evaluation of antitumor response during hormonal therapy of breast cancer.
    J Clin Oncol. 1995 May;13(5):1123-8 PMID: 7537797
  97. Image analysis of androgen receptor immunostaining in metastatic prostate cancer. Heterogeneity as a predictor of response to hormonal therapy.
    Cancer. 1993 Apr 15;71(8):2574-80 PMID: 7680949
  98. Utilization of labeled thymidine in DNA synthesis: studies for PET.
    J Nucl Med. 1990 Mar;31(3):337-42 PMID: 2308005
  99. Positron Emission Tomography: Current Role for Diagnosis and Therapy Monitoring in Oncology.
    Oncologist. 1997;2(6):381-388 PMID: 10388073
  100. Tumor receptor imaging: proceedings of the National Cancer Institute workshop, review of current work, and prospective for further investigations.
    Clin Cancer Res. 1995 Aug;1(8):921-32 PMID: 9816063
  101. Synthesis of [18F]fluoroalanine and [18F]fluorotamoxifen for imaging breast tumors.
    J Drug Target. 1993;1(3):259-67 PMID: 8069568
  102. Oestrogen receptors in meningiomas: a correlative PET and immunohistochemical study.
    Nucl Med Commun. 1997 Jul;18(7):606-15 PMID: 9342097
  103. Breast cancer: PET imaging of estrogen receptors.
    Radiology. 1988 Oct;169(1):45-8 PMID: 3262228
  104. Pathological assessment of response to induction chemotherapy in breast cancer.
    Cancer Res. 1986 May;46(5):2578-81 PMID: 3697997
  105. Measurement of short-term 11C-thymidine activity in human head and neck tumours using positron emission tomography (PET).
    Acta Oncol. 1992;31(5):539-43 PMID: 1419100
  106. Research and clinical potential of receptor based radiopharmaceuticals.
    J Nucl Med. 1985 Jun;26(6):655-62 PMID: 2987443
  107. Characterization of the uptake of 16 alpha-([18F]fluoro)-17 beta-estradiol in DMBA-induced mammary tumors.
    Int J Rad Appl Instrum B. 1987;14(1):15-25 PMID: 3108199
  108. Preparation of four fluorine- 18-labeled estrogens and their selective uptakes in target tissues of immature rats.
    J Nucl Med. 1984 Nov;25(11):1212-21 PMID: 6092569
  109. Carbon-11-methionine and PET in evaluation of treatment response of breast cancer.
    Br J Cancer. 1993 Apr;67(4):787-91 PMID: 8471437
  110. Nuclear medicine in cancer diagnosis.
    Lancet. 1999 Sep 4;354(9181):853-7 PMID: 10485742
  111. Titration of the in vivo uptake of 16 alpha-[18F]fluoroestradiol by target tissues in the rat: competition by tamoxifen, and implications for quantitating estrogen receptors in vivo and the use of animal models in receptor-binding radiopharmaceutical development.
    Nucl Med Biol. 1993 Aug;20(6):735-45 PMID: 8401374
  112. The role of positron emission tomography imaging in early assessment of the antitumor impact of biologics and cytotoxics.
    Curr Opin Oncol. 1994 Nov;6(6):627-32 PMID: 7827177
  113. A critical evaluation of the use of androgen receptor assays to predict the androgen responsiveness of prostatic cancer.
    Prog Clin Biol Res. 1987;239:155-87 PMID: 3309954
  114. 11C-carbon dioxide fixation and equilibration in rat brain: effects on acid-base measurements.
    Neurology. 1982 Apr;32(4):451-4 PMID: 6801543
  115. Fluorine-18-labeled progestin 16 alpha, 17 alpha-dioxolanes: development of high-affinity ligands for the progesterone receptor with high in vivo target site selectivity.
    J Med Chem. 1995 Jan 20;38(2):328-37 PMID: 7830275
  116. [Methyl-11C]thymidine positron emission tomography in tumoral and non-tumoral cerebral lesions.
    Acta Neurol Belg. 1999 Jun;99(2):118-25 PMID: 10427354
  117. The clinical applications of cell kinetics in cancer therapy.
    Annu Rev Pharmacol Toxicol. 1977;17:529-43 PMID: 326172
  118. Monitoring tumour response.
    Eur Radiol. 1996;6(6):775-85 PMID: 8972311
  119. In vitro determination of thymidine-3H labeling index in human solid tumors.
    Cancer Res. 1974 Jun;34(6):1376-80 PMID: 4363655
  120. Tissue-specific expression of the rat androgen-binding protein/sex hormone-binding globulin gene in transgenic mice.
    Mol Cell Endocrinol. 1993 Oct;96(1-2):69-73 PMID: 8276140
  121. Independent blood-brain barrier transport systems for nucleic acid precursors.
    Biochim Biophys Acta. 1975 Jun 25;394(2):211-9 PMID: 1138930
  122. PET with L-[1-carbon-11]-tyrosine to visualize tumors and measure protein synthesis rates.
    J Nucl Med. 1997 Feb;38(2):191-5 PMID: 9025733
  123. Fluorine-18-labeled androgens: radiochemical synthesis and tissue distribution studies on six fluorine-substituted androgens, potential imaging agents for prostatic cancer.
    J Nucl Med. 1992 May;33(5):724-34 PMID: 1569482
  124. Radiolabelled fluoromisonidazole as an imaging agent for tumor hypoxia.
    Int J Radiat Oncol Biol Phys. 1989 Nov;17(5):985-91 PMID: 2808061
  125. Measurement of [methyl-carbon-11]thymidine and its metabolites in head and neck tumors.
    J Nucl Med. 1995 May;36(5):880-2 PMID: 7738667
  126. Multiple estrogen receptor assays in human breast cancer.
    Cancer Res. 1983 Jan;43(1):413-6 PMID: 6847780
  127. The effects of sex hormone binding globulin (SHBG) on testosterone transport into the cerebrospinal fluid.
    J Steroid Biochem Mol Biol. 1992 Jul;42(6):629-35 PMID: 1637726
  128. Progesterone-binding proteins: in vitro binding and biological activity of different steroidal ligands.
    Acta Endocrinol (Copenh). 1975 Mar;78(3):574-92 PMID: 164094
  129. The development of gamma-emitting hormone analogs as imaging agents for receptor-positive tumors.
    Prog Clin Biol Res. 1981;75B:313-27 PMID: 6275413
  130. A model for compartmentation of de novo and salvage thymidine nucleotide pools in mammalian cells.
    Proc Natl Acad Sci U S A. 1975 Sep;72(9):3333-6 PMID: 1059118
  131. Interactions of 16alpha-[18F]-fluoroestradiol (FES) with sex steroid binding protein (SBP).
    Nucl Med Biol. 1999 Nov;26(8):905-13 PMID: 10708304
  132. Iodohexestrols. II. Characterization of the binding and estrogenic activity of iodinated hexestrol derivatives, in vitro and in vivo.
    Biochemistry. 1975 Apr 22;14(8):1742-50 PMID: 164893
  133. Imaging, biodistribution and therapy potential of halogenated tamoxifen analogues.
    Life Sci. 1994;55(1):53-67 PMID: 8015349
  134. Imaging proliferation in vivo with [F-18]FLT and positron emission tomography.
    Nat Med. 1998 Nov;4(11):1334-6 PMID: 9809561
Article Info
Journal
Neoplasia (New York, N.Y.)
Abbr.
Neoplasia
ISSN
1522-8002
DOI
10.1038/sj.neo.7900075
Published
2000-00-00
Pages
71-88
Language
English
Region
United States
NLM ID
100886622
PMCID
PMC1531868
Subset
IM
Grants
NCI NIH HHS · CA25386 · United States
NCI NIH HHS · R01 CA072064 · United States
NCI NIH HHS · R01 CA039566 · United States
NCI NIH HHS · K24 CA082645 · United States
NCI NIH HHS · CA42045 · United States
NCI NIH HHS · CA72064 · United States
NCI NIH HHS · P01 CA042045 · United States
External Links
PubMed source DOI: 10.1038/sj.neo.7900075 PMC Full Text
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: [email protected]

Copyright © 2026.Genelibs Jinan Honghui Biotechnology Co., Ltd. 鲁ICP备20007159号-2